File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)

Conference Paper: The Association Between the Use of Oral Fluoroquinolones and Neuropsychiatric Events: A Self‐Controlled Case Series Study

TitleThe Association Between the Use of Oral Fluoroquinolones and Neuropsychiatric Events: A Self‐Controlled Case Series Study
Authors
Issue Date2016
PublisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/5669
Citation
The 32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE 2016), Dublin, Ireland, 25-28 August 2016. In Pharmacoepidemiology and Drug Safety, 2016, v. 25 n. suppl. 3, p. 551-552, abstract no. 948 How to Cite?
AbstractBackground: Oral fluoroquinolones (FQ) have been reported to be associated with the acute neuropsychiatric events in numerous case reports. However, few population‐based studies have investigated this association. Objectives: To estimate the incidence rate ratio (IRR) of acute neuropsychiatric events among patients prescribed oral FQ in Hong Kong. Methods: We used the self‐controlled case series method to conduct the analysis using data collected from the Clinical Data Analysis and Report System in Hong Kong. Patients with at least one oral FQ prescription and a neuropsychiatric event between 2001‐2013 were identified. Those with a history of neuropsychiatric events were excluded. The rates of event occurrence during risk periods were compared to the non‐risk periods to estimate the IRR. The risk periods were predefined as before, during and after FQ exposure. Poisson regression adjusted for age was used. The crude absolute risk of having a neuropsychiatric event during current FQ use was also estimated. Results: There were 291,751 oral FQ prescribed to 166,325 patients between 2001‐2013. A total of 4,287 patients were included in the analysis. An increased risk was observed in current FQ use [IRR: 2.12 (95% Confidence Interval 1.58‐2.83)] and 1‐7 days immediately after FQ completion [1.90 (1.30‐2.75)]. There was no increased risk observed in other risk periods. A total of 50 neuropsychiatric events occurred during current FQ use. The estimated crude absolute risk of having a neuropsychiatric event during current FQ use was 1.70 (1.30‐2.26) case per 10,000 oral FQ prescriptions. Conclusions: The findings of this study supports an association between the use of oral FQ and neuropsychiatric events. The association is acute and appeared to be short‐term. However, based on the estimated crude absolute risk, the occurrence of such event is rare.
DescriptionPoster Session C: Safety & Effectiveness - Anti-infectives
John Snow Award Recipient
Persistent Identifierhttp://hdl.handle.net/10722/229969
ISSN
2019 Impact Factor: 2.918
2015 SCImago Journal Rankings: 1.804
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChui, SLC-
dc.contributor.authorWong, ICK-
dc.contributor.authorWong, YS-
dc.contributor.authorLee, HME-
dc.contributor.authorChang, WC-
dc.contributor.authorChen, EYH-
dc.contributor.authorChan, EWY-
dc.date.accessioned2016-08-23T14:14:23Z-
dc.date.available2016-08-23T14:14:23Z-
dc.date.issued2016-
dc.identifier.citationThe 32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE 2016), Dublin, Ireland, 25-28 August 2016. In Pharmacoepidemiology and Drug Safety, 2016, v. 25 n. suppl. 3, p. 551-552, abstract no. 948-
dc.identifier.issn1053-8569-
dc.identifier.urihttp://hdl.handle.net/10722/229969-
dc.descriptionPoster Session C: Safety & Effectiveness - Anti-infectives-
dc.descriptionJohn Snow Award Recipient-
dc.description.abstractBackground: Oral fluoroquinolones (FQ) have been reported to be associated with the acute neuropsychiatric events in numerous case reports. However, few population‐based studies have investigated this association. Objectives: To estimate the incidence rate ratio (IRR) of acute neuropsychiatric events among patients prescribed oral FQ in Hong Kong. Methods: We used the self‐controlled case series method to conduct the analysis using data collected from the Clinical Data Analysis and Report System in Hong Kong. Patients with at least one oral FQ prescription and a neuropsychiatric event between 2001‐2013 were identified. Those with a history of neuropsychiatric events were excluded. The rates of event occurrence during risk periods were compared to the non‐risk periods to estimate the IRR. The risk periods were predefined as before, during and after FQ exposure. Poisson regression adjusted for age was used. The crude absolute risk of having a neuropsychiatric event during current FQ use was also estimated. Results: There were 291,751 oral FQ prescribed to 166,325 patients between 2001‐2013. A total of 4,287 patients were included in the analysis. An increased risk was observed in current FQ use [IRR: 2.12 (95% Confidence Interval 1.58‐2.83)] and 1‐7 days immediately after FQ completion [1.90 (1.30‐2.75)]. There was no increased risk observed in other risk periods. A total of 50 neuropsychiatric events occurred during current FQ use. The estimated crude absolute risk of having a neuropsychiatric event during current FQ use was 1.70 (1.30‐2.26) case per 10,000 oral FQ prescriptions. Conclusions: The findings of this study supports an association between the use of oral FQ and neuropsychiatric events. The association is acute and appeared to be short‐term. However, based on the estimated crude absolute risk, the occurrence of such event is rare.-
dc.languageeng-
dc.publisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/5669-
dc.relation.ispartofPharmacoepidemiology and Drug Safety-
dc.titleThe Association Between the Use of Oral Fluoroquinolones and Neuropsychiatric Events: A Self‐Controlled Case Series Study-
dc.typeConference_Paper-
dc.identifier.emailChui, SLC: cslchui@hku.hk-
dc.identifier.emailWong, ICK: wongick@hku.hk-
dc.identifier.emailLee, HME: edwinlhm@hku.hk-
dc.identifier.emailChang, WC: changwc@hku.hk-
dc.identifier.emailChen, EYH: eyhchen@hku.hk-
dc.identifier.emailChan, EWY: ewchan@hku.hk-
dc.identifier.authorityChui, SLC=rp02527-
dc.identifier.authorityWong, ICK=rp01480-
dc.identifier.authorityLee, HME=rp01575-
dc.identifier.authorityChang, WC=rp01465-
dc.identifier.authorityChen, EYH=rp00392-
dc.identifier.authorityChan, EWY=rp01587-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1002/pds.4070-
dc.identifier.hkuros260139-
dc.identifier.hkuros274981-
dc.identifier.volume25-
dc.identifier.issuesuppl. 3-
dc.identifier.spage551, abstract no. 948-
dc.identifier.epage552, abstract no. 948-
dc.identifier.isiWOS:000385483503210-
dc.publisher.placeUnited Kingdom-
dc.identifier.issnl1053-8569-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats